Open Payments

California Pacific Medical Center

Type
Teaching hospital
Where
SAN FRANCISCO, CA
Medicare CCN
050047
Received
$2,572,542 in 190 records, 2021 ($256,182 general, $2,316,360 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment8$256,182
2021Research payment182$2,316,360

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC10$1,313,2832021
Edwards Lifesciences Corporation47$372,0522021
Jenavalve Technology, Inc.1$242,0562021
E.R. Squibb & Sons, L.L.C.11$196,0432021
Genentech, Inc.38$95,9402021
Medtronic, Inc.11$55,8562021
Intercept Pharmaceuticals, Inc.17$52,8432021
Partner Therapeutics, Inc.3$51,0512021
Regeneron Pharmaceuticals, Inc.8$47,1982021
ModernaTX, Inc.5$44,6782021
Novocure Inc.4$26,9252021
PFIZER INC.2$14,5712021
Alexion Pharmaceuticals, Inc.4$12,4612021
Sirtex Medical Inc5$10,7552021
Roche Products Limited1$10,0502021
F. Hoffmann-La Roche AG3$5,9392021
ARRAY BIOPHARMA INC5$5,1232021
SK Life Science, Inc.5$4,1172021
MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC.1$3,4502021
Takeda Pharmaceuticals U.S.A., Inc.2$2,5002021
Eli Lilly and Company1$1,6702021
Chiesi USA, Inc.1$1,5002021
Amgen Inc.1$1,3602021
CSL Behring1$6042021
Johnson & Johnson Health Care Systems Inc.2$4932021
Bio-Rad Laboratories, Inc.1$182021

By nature of payment

NatureRecordsAmount
Research payment182$2,316,360
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$242,056
Consulting Fee2$9,950
Long term medical supply or device loan1$2,164
Space rental or facility fees (teaching hospital only)1$1,500
Debt forgiveness3$511

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31Merck Sharp & Dohme LLC$448,142Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2021
2021-12-31Merck Sharp & Dohme LLC$145,256Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2021
2021-12-31Merck Sharp & Dohme LLC$53,279Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb2021
2021-12-31Merck Sharp & Dohme LLC$38,946Research paymentIn-kind items and services Drug, ONCOLOGYA Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb2021
2021-12-31Merck Sharp & Dohme LLC$21,191Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2021
2021-12-31Merck Sharp & Dohme LLC$19,592Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2021
2021-12-22Merck Sharp & Dohme LLC$38,033Research paymentCash or cash equivalent Drug, ONCOLOGYA Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb2021
2021-12-21Merck Sharp & Dohme LLC$28,085Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2021
2021-12-17Merck Sharp & Dohme LLC$271,089Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2021
2021-12-16Edwards Lifesciences Corporation$20,603Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2021
2021-12-16Intercept Pharmaceuticals, Inc.$8,833Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-12-16Medtronic, Inc.$888Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsOptimize Pro2021
2021-12-15Medtronic, Inc.$16,500Research paymentCash or cash equivalentTricuspid 35 Fr TF EFS2021
2021-12-09Edwards Lifesciences Corporation$2,000Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072021
2021-12-09Edwards Lifesciences Corporation$650Research paymentCash or cash equivalentSM3 Trial 2017-032021
2021-12-09Intercept Pharmaceuticals, Inc.$395Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-12-06Edwards Lifesciences Corporation$7,587Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072021
2021-12-06Edwards Lifesciences Corporation$1,550Research paymentCash or cash equivalentSM3 Trial 2017-032021
2021-12-03Regeneron Pharmaceuticals, Inc.$15,244Research paymentCash or cash equivalentA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2021
2021-12-03Regeneron Pharmaceuticals, Inc.$7,155Research paymentCash or cash equivalentA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2021
2021-12-03Genentech, Inc.$1,701Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-12-02Regeneron Pharmaceuticals, Inc.$1,400Research paymentCash or cash equivalentA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2021
2021-12-01Medtronic, Inc.$650Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsOptimize Pro2021
2021-11-26ARRAY BIOPHARMA INC$2,000Research paymentCash or cash equivalentBRAFTOVI Drug, ONCOLOGYA PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE2021
2021-11-26ARRAY BIOPHARMA INC$650Research paymentCash or cash equivalentBRAFTOVI Drug, ONCOLOGYA PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE2021
2021-11-26ARRAY BIOPHARMA INC$573Research paymentCash or cash equivalentBRAFTOVI Drug, ONCOLOGYA PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE2021
2021-11-26Edwards Lifesciences Corporation$364Research paymentCash or cash equivalentSM3 Trial 2017-032021
2021-11-24Regeneron Pharmaceuticals, Inc.$10,349Research paymentCash or cash equivalentA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2021
2021-11-19Edwards Lifesciences Corporation$5,625Consulting FeeCash or cash equivalent2021
2021-11-19Edwards Lifesciences Corporation$4,325Consulting FeeCash or cash equivalent2021
2021-11-19Genentech, Inc.$656Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2021
2021-11-10PFIZER INC.$9,216Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT2021
2021-11-05ModernaTX, Inc.$22,805Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2021
2021-11-04Genentech, Inc.$3,500Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS2021
2021-11-04Edwards Lifesciences Corporation$2,200Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2021
2021-11-04Edwards Lifesciences Corporation$1,950Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2021
2021-11-03ModernaTX, Inc.$394Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2021
2021-10-28Edwards Lifesciences Corporation$2,775Research paymentCash or cash equivalentCLASP IID 2018-072021
2021-10-26Partner Therapeutics, Inc.$39,501Research paymentCash or cash equivalentLEUKINE Drug, Hematology/OncologyiLEUK Pulm2021
2021-10-26Johnson & Johnson Health Care Systems Inc.$0Debt forgivenessIn-kind items and services2021
2021-10-22Partner Therapeutics, Inc.$1,500Research paymentCash or cash equivalentLEUKINE Drug, Hematology/OncologyiLEUK Pulm2021
2021-10-18Edwards Lifesciences Corporation$7,292Research paymentCash or cash equivalentPartner3 2015-082021
2021-10-18Edwards Lifesciences Corporation$650Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2021
2021-10-14Edwards Lifesciences Corporation$5,288Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2021
2021-10-14Alexion Pharmaceuticals, Inc.$3,925Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli2021
2021-10-14Alexion Pharmaceuticals, Inc.$3,700Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli2021
2021-10-14Edwards Lifesciences Corporation$500Research paymentCash or cash equivalentEVOQUE TR 2019-062021
2021-10-14Edwards Lifesciences Corporation$337Research paymentCash or cash equivalentEVOQUE TR 2019-062021
2021-10-13ModernaTX, Inc.$20,478Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2021
2021-10-05Genentech, Inc.$1,950Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-09-29Intercept Pharmaceuticals, Inc.$4,480Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-09-29Intercept Pharmaceuticals, Inc.$220Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-09-27Roche Products Limited$10,050Research paymentCash or cash equivalentEsbriet Biological, ImmunologyTRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS2021
2021-09-27F. Hoffmann-La Roche AG$2,939Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2021
2021-09-23Edwards Lifesciences Corporation$38,267Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072021
2021-09-23Edwards Lifesciences Corporation$3,901Research paymentCash or cash equivalentSM3 Trial 2017-032021
2021-09-23Edwards Lifesciences Corporation$1,900Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2021
2021-09-22Regeneron Pharmaceuticals, Inc.$1,550Research paymentCash or cash equivalentA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2021
2021-09-21Genentech, Inc.$2,011Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-09-20Edwards Lifesciences Corporation$2,850Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2021
2021-09-16E.R. Squibb & Sons, L.L.C.$1,080Research paymentCash or cash equivalentOPDIVO Biological, OncologyPh III registrational study in 1L HCC nivo monotherapy2021
2021-09-14Medtronic, Inc.$2,110Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsOptimize Pro2021
2021-09-13Genentech, Inc.$1,682Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2021
2021-09-13Edwards Lifesciences Corporation$270Research paymentCash or cash equivalentCLASP IID 2018-072021
2021-09-07E.R. Squibb & Sons, L.L.C.$3,307Research paymentCash or cash equivalentOPDIVO Biological, OncologyPh IIb 2L Bladder Registrational2021
2021-09-02MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC.$3,450Research paymentCash or cash equivalentSAFETY STUDY OF ORAL EDARAVONE ADMINISTERED IN SUBJECTS WITH ALS2021
2021-08-31Medtronic, Inc.$12,000Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsSMART Trial2021
2021-08-26PFIZER INC.$5,355Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT2021
2021-08-26Intercept Pharmaceuticals, Inc.$2,712Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-08-18Genentech, Inc.$27Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2021
2021-08-12Edwards Lifesciences Corporation$16,269Research paymentCash or cash equivalentPartner3 2015-082021
2021-08-11Alexion Pharmaceuticals, Inc.$1,900Research paymentCash or cash equivalentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension 2021
2021-08-11Genentech, Inc.$500Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB2021
2021-08-05Intercept Pharmaceuticals, Inc.$922Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-08-05Edwards Lifesciences Corporation$837Research paymentCash or cash equivalentCLASP IID 2018-072021
2021-08-05Edwards Lifesciences Corporation$837Research paymentCash or cash equivalentCLASP IID 2018-072021
2021-08-04Genentech, Inc.$2,709Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2021
2021-08-04SK Life Science, Inc.$2,544Research paymentCash or cash equivalentXCOPRI Drug, Neurology0595662021
2021-08-03SK Life Science, Inc.$33Research paymentCash or cash equivalentXCOPRI Drug, Neurology0595662021
2021-08-02Genentech, Inc.$950Research paymentCash or cash equivalent DrugTENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS2021
2021-07-29Intercept Pharmaceuticals, Inc.$2,770Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-07-28Genentech, Inc.$31,573Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2021
2021-07-28Novocure Inc.$7,993Research paymentCash or cash equivalentEF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2021
2021-07-28Novocure Inc.$6,788Research paymentCash or cash equivalentEF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2021
2021-07-16Novocure Inc.$11,082Research paymentCash or cash equivalentEF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2021
2021-07-08Edwards Lifesciences Corporation$75,687Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072021
2021-07-08Edwards Lifesciences Corporation$1,250Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2021
2021-07-08Edwards Lifesciences Corporation$650Research paymentCash or cash equivalentSM3 Trial 2017-032021
2021-07-07ModernaTX, Inc.$500Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2021
2021-07-07ModernaTX, Inc.$500Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2021
2021-07-06F. Hoffmann-La Roche AG$2,000Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2021
2021-07-06Genentech, Inc.$1,251Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-06-24Intercept Pharmaceuticals, Inc.$5,950Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-06-21Edwards Lifesciences Corporation$8,316Research paymentCash or cash equivalentPARTNER3 2015-082021
2021-06-21Edwards Lifesciences Corporation$500Research paymentCash or cash equivalentPARTNER3 2015-082021
2021-06-17Edwards Lifesciences Corporation$6,669Research paymentCash or cash equivalentSM3 Trial 2017-032021
2021-06-14Genentech, Inc.$1,000Research paymentCash or cash equivalentHerceptin Biological, BioOncologyPERJETA SAFETY STUDY IN NEO ADJUVANT BC2021
2021-06-10Regeneron Pharmaceuticals, Inc.$5,500Research paymentCash or cash equivalentA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2021
2021-06-10Regeneron Pharmaceuticals, Inc.$3,500Research paymentCash or cash equivalentA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2021
2021-06-10Regeneron Pharmaceuticals, Inc.$2,500Research paymentCash or cash equivalentA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2021
2021-06-10Intercept Pharmaceuticals, Inc.$750Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-06-09Medtronic, Inc.$1,550Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsOptimize Pro2021
2021-06-08E.R. Squibb & Sons, L.L.C.$675Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Nivo ipi vs Nivo in Stage IIIb c or IV Adjuvant Melanoma2021
2021-06-08Medtronic, Inc.$574Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsOptimize Pro2021
2021-06-07Edwards Lifesciences Corporation$1,980Research paymentCash or cash equivalentPartner3 2015-082021
2021-06-04Merck Sharp & Dohme LLC$249,665Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYPhase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin2021
2021-06-03Intercept Pharmaceuticals, Inc.$750Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-05-28Edwards Lifesciences Corporation$4,583Research paymentCash or cash equivalentSM3 Trial 2017-032021
2021-05-28Eli Lilly and Company$1,670Research paymentCash or cash equivalentCYRAMZA Drug, OncologyRANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RAMUCIRUMAB AND BEST SUPPORTIVE CARE -BSC- VERSUS PLACEBO2021
2021-05-27Intercept Pharmaceuticals, Inc.$3,780Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-05-27Chiesi USA, Inc.$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentKENGREAL Drug, CARDIOVASCULAR2021
2021-05-27Edwards Lifesciences Corporation$1,000Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072021
2021-05-27Bio-Rad Laboratories, Inc.$18Debt forgivenessCash or cash equivalentLiquichek Device, Controls2021
2021-05-24Edwards Lifesciences Corporation$1,550Research paymentCash or cash equivalentSM3 Trial 2017-032021
2021-05-24Johnson & Johnson Health Care Systems Inc.$493Debt forgivenessIn-kind items and services2021
2021-05-21E.R. Squibb & Sons, L.L.C.$11,725Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Melanoma 2 3L IPI Progressors2021
2021-05-21Genentech, Inc.$820Research paymentCash or cash equivalent DrugPHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE2021
2021-05-21ARRAY BIOPHARMA INC$650Research paymentCash or cash equivalentBRAFTOVI Drug, ONCOLOGYA PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE2021
2021-05-17Sirtex Medical Inc$135Research paymentCash or cash equivalentSIR-Spheres Microspheres Device, Interventional OncologyRadiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study2021
2021-05-12Sirtex Medical Inc$4,715Research paymentCash or cash equivalentSIR-Spheres Microspheres Device, Interventional OncologyRadiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study2021
2021-05-10Novocure Inc.$1,061Research paymentCash or cash equivalentEF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2021
2021-05-06Edwards Lifesciences Corporation$6,054Research paymentCash or cash equivalentCLASP IID 2018-072021
2021-05-06Intercept Pharmaceuticals, Inc.$120Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-05-03Genentech, Inc.$615Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-04-23Medtronic, Inc.$2,164Long term medical supply or device loanIn-kind items and servicesEmprint Device, Ablation2021
2021-04-23Genentech, Inc.$600Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB2021
2021-04-22Amgen Inc.$1,360Research paymentCash or cash equivalentGALACTIC - HF2021
2021-04-21ARRAY BIOPHARMA INC$1,250Research paymentCash or cash equivalentBRAFTOVI Drug, ONCOLOGYA PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE2021
2021-04-16Takeda Pharmaceuticals U.S.A., Inc.$2,220Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-04-15Intercept Pharmaceuticals, Inc.$6,932Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-04-15Alexion Pharmaceuticals, Inc.$2,936Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli2021
2021-04-15Edwards Lifesciences Corporation$837Research paymentCash or cash equivalentCLASP IID 2018-072021
2021-04-05Edwards Lifesciences Corporation$64,449Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072021
2021-04-05Edwards Lifesciences Corporation$22,990Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2021
2021-03-30Genentech, Inc.$3,335Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-03-30Genentech, Inc.$1,865Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-03-27Genentech, Inc.$2,120Research paymentCash or cash equivalent DrugPHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA2021
2021-03-27Genentech, Inc.$750Research paymentCash or cash equivalent DrugPHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA2021
2021-03-27Genentech, Inc.$500Research paymentCash or cash equivalent DrugPHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA2021
2021-03-18Edwards Lifesciences Corporation$25,315Research paymentCash or cash equivalentPartner3 2015-082021
2021-03-18Edwards Lifesciences Corporation$14,087Research paymentCash or cash equivalentSM3 Trial 2017-032021
2021-03-18Intercept Pharmaceuticals, Inc.$3,695Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-03-16Genentech, Inc.$1,375Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyA PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER2021
2021-03-11Edwards Lifesciences Corporation$837Research paymentCash or cash equivalentCLASP IID 2018-072021
2021-03-11Edwards Lifesciences Corporation$650Research paymentCash or cash equivalentSM3 Trial 2017-032021
2021-03-09CSL Behring$604Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2021
2021-03-08Medtronic, Inc.$4,969Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsOptimize Pro2021
2021-03-06Genentech, Inc.$8,550Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2021
2021-03-06Genentech, Inc.$3,500Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2021
2021-03-05Genentech, Inc.$1,000Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyA PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER2021
2021-03-01Sirtex Medical Inc$2,800Research paymentCash or cash equivalentSIR-Spheres Microspheres Device, Interventional OncologyRadiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study2021
2021-03-01Sirtex Medical Inc$2,160Research paymentCash or cash equivalentSIR-Spheres Microspheres Device, Interventional OncologyRadiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study2021
2021-03-01Sirtex Medical Inc$945Research paymentCash or cash equivalentSIR-Spheres Microspheres Device, Interventional OncologyRadiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study2021
2021-03-01Edwards Lifesciences Corporation$837Research paymentCash or cash equivalentCLASP IID 2018-072021
2021-02-25Intercept Pharmaceuticals, Inc.$8,635Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-02-23Genentech, Inc.$3,990Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-02-23Genentech, Inc.$167Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-02-19Genentech, Inc.$1,157Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-02-19Genentech, Inc.$1,157Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-02-19Genentech, Inc.$280Research paymentCash or cash equivalentHerceptin Biological, BioOncologyPERJETA SAFETY STUDY IN NEO ADJUVANT BC2021
2021-02-18Edwards Lifesciences Corporation$1,300Research paymentCash or cash equivalentSM3 Trial 2017-032021
2021-02-18Edwards Lifesciences Corporation$1,000Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072021
2021-02-11E.R. Squibb & Sons, L.L.C.$10,372Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Adjuvant Melanoma Monotherapy2021
2021-02-11E.R. Squibb & Sons, L.L.C.$2,325Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Adjuvant HCC mono vs placebo2021
2021-02-09Medtronic, Inc.$1,900Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsOptimize Pro2021
2021-02-08E.R. Squibb & Sons, L.L.C.$7,483Research paymentCash or cash equivalentA PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF22021
2021-02-08E.R. Squibb & Sons, L.L.C.$1,869Research paymentCash or cash equivalentA PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF22021
2021-02-08F. Hoffmann-La Roche AG$1,000Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2021
2021-02-04Intercept Pharmaceuticals, Inc.$1,852Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-02-03Genentech, Inc.$500Research paymentCash or cash equivalent DrugPHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE2021
2021-02-02E.R. Squibb & Sons, L.L.C.$128,799Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Adjuvant Melanoma Stage II B C Opdivo Mono2021
2021-02-02E.R. Squibb & Sons, L.L.C.$16,405Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase II 1L Mel - IPI Combo2021
2021-02-02E.R. Squibb & Sons, L.L.C.$12,000Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Stage III Unresectable NSCLC Combo2021
2021-02-02Genentech, Inc.$1,655Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-02-02Genentech, Inc.$606Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-02-02Genentech, Inc.$167Research paymentCash or cash equivalent DrugGDC0068 COMB W TAXOTERE OR FOLFOX2021
2021-02-01Genentech, Inc.$2,842Research paymentCash or cash equivalent DrugPHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE2021
2021-01-28Edwards Lifesciences Corporation$1,337Research paymentCash or cash equivalentCLASP IID 2018-072021
2021-01-22Jenavalve Technology, Inc.$242,056Compensation for services other than consulting, including serving as faculty or as a speaker at a v (8 payments)Cash or cash equivalentJenaValve Pericardial TAVR System Device, Cardiology2021
2021-01-22Genentech, Inc.$841Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2021
2021-01-21Intercept Pharmaceuticals, Inc.$39Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-01-20Partner Therapeutics, Inc.$10,050Research paymentCash or cash equivalentLEUKINE Drug, Hematology/OncologyiLEUK Pulm2021
2021-01-14Medtronic, Inc.$12,551Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsOptimize Pro2021
2021-01-11Edwards Lifesciences Corporation$1,337Research paymentCash or cash equivalentCLASP IID 2018-072021
2021-01-08Takeda Pharmaceuticals U.S.A., Inc.$280Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2021
2021-01-06Genentech, Inc.$6,500Research paymentCash or cash equivalent DrugPHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA2021
2021-01-06Genentech, Inc.$1,532Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2021
2021-01-05SK Life Science, Inc.$675Research paymentCash or cash equivalentXCOPRI Drug, Neurology1-FA77592021
2021-01-05SK Life Science, Inc.$600Research paymentCash or cash equivalentXCOPRI Drug, Neurology1-FA77592021
2021-01-05SK Life Science, Inc.$265Research paymentCash or cash equivalentXCOPRI Drug, Neurology1-FA77592021

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.0% in Oct 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.